These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 20830493)

  • 21. Severity of restless legs syndrome is inversely correlated with echogenicity of the substantia nigra in different neurodegenerative movement disorders. a preliminary observation.
    Pedroso JL; Bor-Seng-Shu E; Felicio AC; Braga-Neto P; Dutra LA; de Aquino CC; Ferraz HB; do Prado GF; Teixeira MJ; Barsottini OG
    J Neurol Sci; 2012 Aug; 319(1-2):59-62. PubMed ID: 22632781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transcranial imaging of substantia nigra hyperechogenicity in a Taiwanese cohort of Parkinson's disease.
    Huang YW; Jeng JS; Tsai CF; Chen LL; Wu RM
    Mov Disord; 2007 Mar; 22(4):550-5. PubMed ID: 17260344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of MPTP-induced substantia nigra hyperechogenicity in Rhesus monkeys by transcranial ultrasound.
    Subramanian T; Lieu CA; Guttalu K; Berg D
    Ultrasound Med Biol; 2010 Apr; 36(4):604-9. PubMed ID: 20211515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does normal substantia nigra echogenicity make a difference in Parkinson's disease diagnosis? A real clinical practice follow-up study.
    Alonso-Canovas A; Lopez-Sendon Moreno JL; Buisan J; Sainz de la Maza S; Costa-Frossard L; Garcia-Ribas G; de Felipe-Mimbrera A; Matute-Lozano MC; Zarza Sanz B; Toledano Delgado R; Corral I; Masjuan J; Martinez-Castrillo JC
    J Neurol; 2018 Oct; 265(10):2363-2369. PubMed ID: 30116942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease.
    Berg D; Merz B; Reiners K; Naumann M; Becker G
    Mov Disord; 2005 Mar; 20(3):383-5. PubMed ID: 15486999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson's disease.
    Schweitzer KJ; Hilker R; Walter U; Burghaus L; Berg D
    Mov Disord; 2006 Jan; 21(1):94-8. PubMed ID: 16114024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Substantia Nigra Echogenicity Associated with Clinical Subtypes of Parkinson's Disease.
    Zhou HY; Huang P; Sun Q; Du JJ; Cui SS; Tan YY; Hu YY; Zhan WW; Wang Y; Xiao Q; Liu J; Chen SD
    J Parkinsons Dis; 2018; 8(2):333-340. PubMed ID: 29614699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Substantia nigra hyperechogenicity as a marker for Parkinson's disease: a population-based study.
    Mahlknecht P; Seppi K; Stockner H; Nocker M; Scherfler C; Kiechl S; Willeit J; Schmidauer C; Gasperi A; Rungger G; Poewe W
    Neurodegener Dis; 2013; 12(4):212-8. PubMed ID: 23689066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term course of substantia nigra hyperechogenicity in Parkinson's disease.
    Behnke S; Runkel A; Kassar HA; Ortmann M; Guidez D; Dillmann U; Fassbender K; Spiegel J
    Mov Disord; 2013 Apr; 28(4):455-9. PubMed ID: 23115064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Transcranial parenchymal sonography in the diagnosis of Parkinson's disease].
    Mijajlović M; Petrović I; Stojković T; Svetel M; Stefanova E; Kostić VS
    Vojnosanit Pregl; 2008 Aug; 65(8):601-5. PubMed ID: 18751340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease.
    Schweitzer KJ; Brüssel T; Leitner P; Krüger R; Bauer P; Woitalla D; Tomiuk J; Gasser T; Berg D
    J Neurol; 2007 May; 254(5):613-6. PubMed ID: 17415511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Sonography of the parenchyma in Parkinson's disease].
    Hagenah J; Seidel G
    Nervenarzt; 2010 Oct; 81(10):1189-95. PubMed ID: 20802993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Substantia nigra echogenicity in Parkinson's disease: relation to serum iron and C-reactive protein.
    Walter U; Witt R; Wolters A; Wittstock M; Benecke R
    J Neural Transm (Vienna); 2012 Jan; 119(1):53-7. PubMed ID: 21626410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathophysiology of transcranial sonography signal changes in the human substantia nigra.
    Double KL; Todd G; Duma SR
    Int Rev Neurobiol; 2010; 90():107-20. PubMed ID: 20692497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical findings of hyperechoic substantia nigra in patients with Parkinson's disease.
    Fan Y; Ma J; Yang D; Li X; Liang K; She Z; Qi X; Shi X; Gu Q; Zheng J; Li D
    Eur J Neurosci; 2024 May; 59(10):2702-2714. PubMed ID: 38469656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic value of combined assessment of olfaction and sustantia nigra hyperechogenicity for Parkinson's disease.
    López Hernández N; García Escrivá A; Shalabi Benavent M
    Neurologia; 2015 Oct; 30(8):496-501. PubMed ID: 24839905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder.
    Iranzo A; Stockner H; Serradell M; Seppi K; Valldeoriola F; Frauscher B; Molinuevo JL; Vilaseca I; Mitterling T; Gaig C; Vilas D; Santamaria J; Högl B; Tolosa E; Poewe W
    Mov Disord; 2014 Dec; 29(14):1774-80. PubMed ID: 25384461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome.
    Schmidauer C; Sojer M; Seppi K; Stockner H; Högl B; Biedermann B; Brandauer E; Peralta CM; Wenning GK; Poewe W
    Ann Neurol; 2005 Oct; 58(4):630-4. PubMed ID: 16037973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Substantia nigra hyperechogenicity in Parkinson's disease.
    Bor-Seng-Shu E; Fonoff ET; Barbosa ER; Teixeira MJ
    Acta Neurochir (Wien); 2010 Dec; 152(12):2085-7. PubMed ID: 20623147
    [No Abstract]   [Full Text] [Related]  

  • 40. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings.
    Berg D; Siefker C; Becker G
    J Neurol; 2001 Aug; 248(8):684-9. PubMed ID: 11569897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.